Headlines about Illumina (NASDAQ:ILMN) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Illumina earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the life sciences company an impact score of 45.2753036023419 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Global Automotive Switches Market 2017-2021 by Vehicle Type – Increasing Demand for Illuminated Automotive Switches – ResearchAndMarkets.com (markets.financialcontent.com)
- Ariosa Liable for $26 Million in Lost Profits for Infringing Two Blood Test Patents (ipwatchdog.com)
- Phase Genomics Unveils a Hi-C Kit for Human Samples, Expanding Their Hi-C Product Portfolio (prweb.com)
- Analyzing Abaxis (ABAX) and Illumina (ILMN) (americanbankingnews.com)
- Do What Institutional Investors Does: Editas Medicine, Inc. (EDIT), Illumina, Inc. (ILMN) – Market Movers (financialqz.com)
Shares of Illumina (ILMN) traded up $3.84 during mid-day trading on Monday, hitting $221.03. The stock had a trading volume of 1,000,188 shares, compared to its average volume of 1,100,000. The stock has a market cap of $32,270.00, a P/E ratio of 44.83, a price-to-earnings-growth ratio of 2.87 and a beta of 0.92. Illumina has a fifty-two week low of $158.02 and a fifty-two week high of $248.97. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.42.
ILMN has been the subject of several research reports. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $184.00 to $228.00 in a report on Wednesday, October 25th. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Barclays boosted their target price on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a report on Wednesday, January 31st. Finally, Cowen boosted their target price on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company. Illumina has a consensus rating of “Buy” and a consensus price target of $241.39.
In related news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now owns 9,088 shares in the company, valued at approximately $2,058,886.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $205.48, for a total value of $410,960.00. Following the completion of the sale, the executive vice president now owns 30,370 shares in the company, valued at approximately $6,240,427.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 117,690 shares of company stock valued at $25,989,564. Company insiders own 0.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Illumina (ILMN) Share Price” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-illumina-ilmn-share-price.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.